Sedana Medical AB (publ) announces that its first pivotal US trial INSPiRE-ICU 1 has met its primary endpoint: to prove that inhaled sedation with isoflurane is an effective sedation method by establi ...
Armata Pharmaceuticals (ARMP) announced “encouraging” topline results from its Phase 2 trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary ...
Based on positive initial results in monotherapy, the Company has amended the KYANITE-1 protocol to add two cohorts evaluating inhaled KB707 for the treatment of advanced NSCLC in combination with ...
MannKind Corporation announces six-month results from phase 3 INHALE-1 of Afrezza inhalation powder in children and adolescents: Danbury, Connecticut Wednesday, December 18, 2024, ...